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PURPOSE. Identification of sensitive biomarkers is essential to determine potential effects of
emerging therapeutic trials for Stargardt disease. This study aimed to describe the natural
history of late-onset Stargardt, and demonstrates the accuracy of retinal pigment epithelium
(RPE) atrophy progression as an outcome measure.
METHODS. We performed a retrospective cohort study collecting multicenter data from 47
patients (91 eyes) with late-onset Stargardt, defined by clinical phenotype, at least one ABCA4
mutation, and age at disease onset ‡ 45 years. We analyzed RPE atrophy progression on
fundus autofluorescence and near-infrared reflectance imaging using semiautomated software
and a linear mixed model. We performed sample size calculations to assess the power in a
simulated 2-year interventional study and assessed visual endpoints using time-to-event
analysis.
RESULTS. Over time, progression of RPE atrophy was observed (mean: 0.22 mm/year, 95%
confidence interval [CI]: 0.19–0.27). By including only patients with bilateral RPE atrophy in a
future trial, 32 patients are needed to reach a power of 83.9% (95% CI: 83.1–84.6), assuming a
fixed therapeutic effect size of 30%. We found a median interval between disease onset and
visual acuity decline to 20/32, 20/80, and 20/200 of 2.74 (95% CI: 0.54–4.41), 10.15 (95% CI:
6.13–11.38), and 11.38 (95% CI: 6.13–13.34) years, respectively.
CONCLUSIONS. We show that RPE atrophy represents a robust biomarker to monitor disease
progression in future therapeutic trials. In contrast, the variability in terms of the course of
visual acuity was high.
Keywords: late-onset Stargardt, fundus autofluorescence, retinal pigment epithelium atrophy,
biomarker, disease progression
Stargardt disease is an autosomal recessive retinal dystrophycaused by mutations in the ABCA4 gene, and affects 1:8000
to 1:10,000 people worldwide.1 Patients generally develop
central loss of vision in childhood or early adulthood.2–4
However, late-onset Stargardt can be diagnosed at age ‡ 45
years, and has been associated with carrying one or two mutant
ABCA4 alleles.5,6 Patients with this late-onset variant may first
present with metamorphopsia or oscillopsia without any
decrease in visual acuity. Occasionally, these patients are
asymptomatic and are coincidentally diagnosed during screen-
ing tests for other retinal diseases, such as glaucoma, diabetes
or thyroid disease.
The natural course of late-onset Stargardt includes a typical
phenotype of yellow-white flecks and retinal pigment epithe-
lium (RPE) atrophy. Patches of atrophy initially occur in the
parafoveal retina and radially expand in size over time. New
atrophic areas can arise; multifocal atrophic areas coalesce.
Atrophic areas can form a ring encircling the intact and still-
functioning fovea. Then, it is only until late in the disease
course that the fovea will be involved in the atrophic
process.7–9 The patient’s fixation point eventually shifts
eccentrically, which leads to a substantial loss of visual acuity.10
However, central atrophy can also develop early in the disease
course, and only minor disease progression has been described
in other patients.5 Indeed, substantial variations in RPE atrophy
progression have been reported before in small groups of
typical Stargardt patients.11 Yet analyses of the natural course of
large late-onset Stargardt cohorts are missing.
In light of recently upcoming therapeutic options for
Stargardt disease,12–14 accurate biomarkers to determine their
potential effects are crucial. The well-defined area of RPE
atrophy is a frequent feature of late-onset Stargardt, showing
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similarities to geographic atrophy in age-related macular
degeneration (AMD). Fundus autofluorescence (FAF) imaging
can clearly visualize such areas of RPE atrophy,15,16 and change
in RPE atrophy over time by FAF has already been accepted as a
clinical endpoint by the U.S. Food and Drug Administration in
AMD.17 We hypothesize that areas of RPE atrophy could also
serve to sensitively monitor the effect of a drug trial in late-
onset Stargardt. This would make patients with late-onset
Stargardt appropriate candidates for upcoming therapeutic
trials. In this study, we describe the natural history in late-onset
Stargardt patients, and identify cohorts based on imaging
parameters that determine the visual course in these patients.
We quantify atrophy progression with semiautomated soft-
ware, previously validated for AMD,18 showing the accuracy of
this outcome measure, and include sample size calculations
that are valuable for the design of upcoming therapeutic trials.
METHODS
Patient Selection
We identified patients from the Stargardt database of the
Department of Ophthalmology at Radboud University Medical
Center (Nijmegen, The Netherlands) and from the participants
in the prospective natural history study Fundus Autofluores-
cence in Age-related Macular Degeneration (FAM;
NCT00393692).
We included 47 patients with a late disease onset, defined
by an age ‡ 45 years at which symptoms were first noticed.5 If
the patient did not report any symptoms, we used the age at
which the patient was diagnosed by an ophthalmologist. We
clinically considered patients to have late-onset Stargardt when
typical yellow-white flecks or dots were seen that correlated
with hyperautofluorescent flecks on 488-nm FAF imaging.
Patients were analyzed for the presence of mutations in the
ATP-binding cassette, subfamily A, member 4 (ABCA4,
NM_000350.2) gene. Clinical diagnosis was confirmed by
genetic testing if at least one ABCA4 mutation was found. We
excluded patients without evidence of ABCA4 mutations. In
patients carrying only one ABCA4 mutation, we performed
additional sequencing of the peripherin-2 gene (PRPH2,
NM_000322.4) to exclude pseudo-Stargardt pattern dystrophy
and central areolar choroidal dystrophy.19,20
This cohort study was carried out with approval from the
Institutional Ethics Committee at Radboud University Medical
Center (Nijmegen, The Netherlands) and the University
Hospital of Bonn (Bonn, Germany), and adhered to the tenets
of the Declaration of Helsinki. All patients provided informed
consent before giving a blood sample and receiving additional
ophthalmologic examinations to complete the clinical assess-
ment.
Clinical Assessment
We reviewed the patients’ records for ophthalmologic history
and available technical examinations, including sex, age at
disease onset, and age at baseline. Best-corrected visual acuity
(BCVA) was measured using a Snellen or Early Treatment
Diabetic Retinopathy Study (ETDRS) chart, then transformed
into the logarithm of the minimum angle of resolution
(logMAR) for subsequent analysis. Fundus characteristics were
documented using fundus photography (Topcon TRC-50IX;
Topcon Corporation, Tokyo, Japan; or Visucam 500; Carl Zeiss
Meditec, Jena, Germany). Fundus autofluorescence (k ¼ 488
nm; emission 500–700 nm) and near-infrared reflectance (NIR;
k ¼ 820 nm) imaging were performed using a confocal
scanning laser ophthalmoscope (Spectralis HRAþOCT or
HRA2; Heidelberg Engineering, Heidelberg, Germany) in a
subset of visits. The field of view was set at 308 3 308 or 558 3
558 and was centered on the macula. Eyes with signs of
choroidal neovascularization were excluded from further
analysis.
Image Grading and Cohorts
For each visit, two independent graders (MF and ML), blinded
to each other’s results, evaluated the status of the fovea and the
presence of clearly demarcated RPE atrophy (analogous to
‘‘definitely decreased autofluorescence,’’ the term recently
used by Kuehlewein et al.21) on all available imaging
modalities. Atrophy was graded as follows: (1) no RPE atrophy
with an intact fovea, (2) extrafoveal (but not fovea encircling)
RPE atrophy, (3) a typical ‘‘foveal sparing’’ phenotype in which
RPE atrophy encircled the fovea by ‡1808,10 or (4) foveal
involvement. Foveal involvement was indicated by a mottled or
absent autofluorescent signal (equaling what was ultimately
termed ‘‘well-/poorly demarcated questionably decreased
autofluorescence’’21). In cases of discrepancy, a third grader
(SL) evaluated the images. His agreement with one of the
independent graders was finally used. Based on this grading,
eyes were exploratively analyzed in order to form cohorts that
might be predictive for visual acuity loss.
Quantitative Measurements of Retinal Pigment
Epithelium Atrophy
Two independent graders (MF and ML), blinded to each other’s
results, performed measurements of the area of RPE atrophy
using the RegionFinder software (version 2.5.5.0, Heidelberg
Engineering) on FAF images, as previously established for
AMD.18 In cases in which the foveal borders of the atrophy
could not be well determined in FAF images, NIR images were
included in the analysis wherever available.22 The final value
was defined as the average of the two measurements between
the readers, provided that the two measurements did not differ
by >0.15 mm2. If the difference exceeded 0.15 mm2, a senior
reader (MMM) additionally performed the measurement.18 We
calculated the final value by averaging the senior reader
measurement along with the closer of the two other reader
measurements.
Statistical Analysis
We analyzed data using SAS Statistical Analysis Software
Version 9.2 (SAS Institute, Cary, NC, USA) and R Version
3.1.2.23 Supplementary Figure S1 gives an overview of the
analytical process applied in this work. Changes in visual acuity
over time were assessed by time-to-event curves (cumulative
distribution functions), and atrophy progression was analyzed
using linear mixed-effects models. We performed a simulation
study for power calculation for possible future interventional
trials. Unless otherwise stated, all values given in the text
represent median, minimum, and maximum values. Groups
were compared by Mann–Whitney U tests. Details on the
statistical procedures can be found in Supplementary Text S1.
RESULTS
Patient Features and Initial Symptoms
A total of 91 eyes of 47 patients (19 men, 28 women) were
included in this study. Two mutations in the ABCA4 gene were
found in 20 patients (42.6%) and one mutation in 27 (57.4%;
Supplementary Table S1). The median age at disease onset was
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54 years (range, 45–84). Self-reported initial symptoms were
obtained for 42 patients and included a decrease in visual
acuity (n ¼ 24; 50%), metamorphopsia (n ¼ 12; 29%),
nyctalopia (n ¼ 5; 12%), paracentral scotomas (n ¼ 4; 10%),
or oscillopsia (n¼ 1; 2%). Twelve patients (29%) did not report
any visual complaints. In five patients, initial symptoms were
not unequivocally denoted in the patient’s file.
Course of Visual Acuity
Overall, visual acuity data were available from 632 eye visits. At
the first presentation after disease onset, the median disease
duration was 0.9 years (range, 0–25.6) with a median BCVA of
0.10 logMAR (range,0.14 to 1.70; Snellen 20/25). The median
follow-up time of the patients with more than a single visit (45
out of 47 patients) was 4.8 years (range, 0.04–25.0). Time-to-
event analysis yielded a median and 95% confidence interval
(CI) between the age at onset and a decline in BCVA to mild
visual impairment (n ¼ 62), moderate visual impairment (n ¼
39), and severe visual impairment (n¼ 35) of 2.74 (0.54–4.41),
10.15 (6.13–11.38), and 11.38 (9.34–13.34) years, respectively
(Fig. 1). The median disease duration at the final visit was 6.8
years (range, 0–30.9). The median BCVA at the final visit was
0.37 logMAR (range, 0.10 to 1.80; Snellen 20/47).
Assessment of Retinal Features
For each patient, clinical imaging data were available for a
subset of visits (241 eye visits of 91 eyes). At baseline (first visit
with imaging data available), yellow-white flecks were
observed in all but one patient, in whom small yellowish
spots were noted. An apparently intact fovea (Fig. 2A) without
mottled or sharply decreased autofluorescence indicating RPE
atrophy was present in 58 eyes. Out of these 58 eyes without
foveal involvement, 22 had no RPE atrophy (Fig. 2B), 16 had
extrafoveal (but not fovea encircling) atrophy (Fig. 2C), and 20
FIGURE 1. Time-to-event curve (computed as 1 minus the Turnbull
estimates) showing the cumulative fraction of eyes in late-onset
Stargardt patients reaching the following clinical endpoints: mild visual
impairment (‡0.2 logMAR, Snellen  20/32; triangle), moderate visual
impairment (‡0.6 logMAR, Snellen  20/80; square), and severe visual
impairment (‡1.0 logMAR, Snellen  20/200; circle). logMAR,
logarithm of the minimum angle of resolution.
FIGURE 2. The assessment of retinal features in late-onset Stargardt patients was done by grading foveal involvement and RPE atrophy. The foveal
signal (triangles) was graded as either (A) ‘‘uninvolved/normal’’ or (E) ‘‘involved’’ (mottled or absent). RPE atrophy (asterisks) was graded as (B)
none, (C) extrafoveal (but not fovea encircling), (D) foveal sparing (‡1808 encircling the fovea), or (F) central RPE atrophy. RPE, retinal pigment
epithelium.
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had a foveal sparing pattern of RPE atrophy encircling the fovea
‡ 1808 (Fig. 2D). The other 32 eyes had an involved fovea by
either a mottled appearance (23 eyes; Fig. 2E) or central RPE
atrophy (9 eyes; Fig. 2F). One eye was excluded because it was
inconclusive if the fovea appeared mottled. There was no
significant difference in patient’s age between eyes that initially
had foveal involvement and those that did not (median: 60.4 [n
¼ 32] and 61.0 years [n¼ 58], respectively; P ¼ 0.421).
Cohorts
Assessment of retinal features over the entire imaging interval
(Table 1) enabled us to categorize the eyes into four clearly
distinctive cohorts. During the entire follow-up period, 20 eyes
(22.2%) showed only flecks without any mottled foveal
alterations or RPE atrophy (cohort I). Eleven eyes (12.2%)
showed extrafoveal (but not fovea encircling) RPE atrophy
(cohort II). Twenty-six eyes (28.9%) developed foveal sparing
(RPE atrophy encircling the fovea ‡ 1808; Cohort III). In four of
these 26 eyes, the fovea eventually involved in the atrophic
process at the last visit. Thirty-three eyes (36.7%) had eventual
foveal involvement without passing through a foveal sparing
phenotype during the observational interval (cohort IV).
The median follow-up periods of the entire imaging interval
of cohorts I, II, III, and IV were 3.4 (range, 0–10.4), 3.3 (range,
0.1–11.7), 8.7 (range, 2.1–30.9), and 11.4 (range, 0.3–30.9)
years, respectively. Eyes in cohorts I and II had a median
disease duration of 3.4 years (range, 0–11.7), which was
shorter (P¼ 1.03 106) than in cohort III and IV (median: 11.0
years; range, 0.3–30.9).
Based on the morphologic observation of distinct cohorts
among collective late-onset Stargardt patients, we further
analyzed eyes with long follow-up grouped into the ‘‘foveal
sparing’’ (cohort III) and ‘‘foveal involvement’’ (cohort IV)
cohorts for possible distinctive long-term visual courses among
these cohorts. Eyes that formed foveal sparing cohort III took
an overall favorable visual course when compared to eyes from
foveal involvement cohort IV. Survival analysis for the
endpoints ‡ 0.2 logMAR, ‡ 0.6 logMAR, and ‡ 1.0 logMAR
showed a notably later, though not significant, occurrence of
each of these events in eyes from foveal sparing cohort III
(Table 2).
Modeling of Retinal Pigment Epithelium Atrophy
We assessed changes in RPE atrophy area over time in a subset
of visits from 66 eyes (from 21 female and 17 male patients).
The median follow-up time with FAF imaging was 2.3 years
(range, 0.07–7.7). Measurement of RPE atrophy size was
possible with high agreement between two independent
readers (Supplementary Fig. S2). At the first visit, the mean
RPE atrophy size was 6.26 mm2 (6 standard deviation: 7.3).
Square root transformed data were used for all further analysis.
Modeling RPE atrophy over time revealed an annual atrophy
progression rate (slope) of 0.22 mm/year (95% CI: 0.19–0.27).
For 28 patients, data on RPE atrophy progression were
available from both eyes for the same observational interval,
and revealed that atrophy progression rates moderately
correlated between the two eyes of a single patient (Pearson’s
r¼ 0.52; Supplementary Fig. S3).
TABLE 1. Retinal Features in Late-Onset Stargardt Over the Entire Observational Interval
At Baseline Clinical Course
Resulting
CohortInitial Features Eyes
Median Visual Acuity,
logMAR (Range) Change in Features
Median Visual Acuity,
Final Visit,
logMAR (Range)
No foveal involvement
No RPE atrophy 22 0.10 (0.20 to 0.64) 20 unchanged 0.06 (0.06 to 0.58) I
2 eyes developed extrafoveal atrophy 0.02 (0.06 to 0.02) II
Extrafoveal but not fovea
encircling
16 0.05 (0.10 to 0.72) 9 unchanged 0.12 (0 to 1.54) II
6 progressed to foveal sparing 0.44 (0.06 to 0.74) III
1 developed foveal involvement 0.36 IV
Foveal sparing encircling
‡ 1808
20 0.12 (0 to 0.52) 16 unchanged 0.22 (0.04 to 1.80) III
4 eyes loss of foveal sparing 1.25 (0.94 to 1.50) III
Foveal involvement
Central RPE atrophy 9 0.98 (0.30 to 1.50) 1.10 (0.80 to 1.50) IV
Mottled 23 0.30 (0.08 to 1.80) 20 eyes unchanged 0.69 (0.10 to 1.72) IV
3 eyes changed to central RPE atrophy 1.30 (1.10 to 1.80) IV
Cohort I had only flecks without any mottled foveal alterations or RPE atrophy; cohort II had extrafoveal (but not fovea encircling) RPE atrophy
until the last visit; cohort III developed foveal sparing (RPE atrophy encircling the fovea ‡ 1808); and cohort IV had foveal involvement by either a
mottled fovea or central RPE atrophy without passing through a foveal sparing phenotype during the observational interval.
TABLE 2. Median Times (Years; 95% Confidence Interval) of Best-Corrected Visual Acuity Decline Since the Age at Onset Compared Between Eyes
of Late-Onset Stargardt Patients Who Developed Foveal Sparing and Those Who Had Early Foveal Involvement
Cohort
Mild Impairment
 20/32, ‡ 0.2 logMAR
Moderate Impairment
 20/80, ‡ 0.6 logMAR
Severe Impairment
 20/200, ‡ 1.0 logMAR
Foveal sparing, cohort III 0.95 (NA*–6.61) years 10.15 (3.09–13.34) years 23.3 (13.6–NA*)
Foveal involvement, cohort IV 0.51 (NA*–4.41) years 7.73 (4.30–22.89) years NA* (24.0–N/A*)
Log-rank test 0.57 0.07 0.06
NA, not available.
* Values could not be calculated, as too many events occurred outside the observational interval.
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Sample Size Calculations
Based on the observed progression kinetics and the agreement
between two eyes of a single individual, we were able to
perform sample size calculations for possible future therapeu-
tic trials. The assumption of a trial duration of 2 years and
inclusion of only patients with bilateral RPE atrophy resulted in
the sample size–power relationship depicted in Figure 3, with
expected effect sizes of 50%, 40%, and 30% reduction in RPE
atrophy progression. For effect sizes of 50% and 40%, fewer
than 25 patients would be needed to obtain a statistical power
of 0.9 at the 5% significance level, while for an effect size of
30%, a power of 0.8 would be reached if at least 32 patients
were included.
DISCUSSION
The natural history of late-onset Stargardt features expanding,
well-demarcated areas of RPE atrophy, which can be a
promising clinical biomarker to monitor disease progression.
Although clinical features have been previously described,5 we
comprehensively report on visual course and specific RPE
atrophy progression rates in a large multicenter cohort that
was well defined by clinical, genetic, and validated imaging
parameters. In addition, we used advanced statistical methods
to deliver robust results,24,25 as these are required for planning
and conducting clinical trials. These measures ensured the
highest levels of data integrity. As a result, this work showed
that a future therapeutic trial can be realized with sufficient
statistical power with a cohort of as few as 35 patients (Fig. 3).
In contrast, visual acuity loss may not be a useful outcome
measure in clinical trials due to its high interindividual
variance2 and overall slow decline; this would result in
unrealistic large cohorts and long follow-up. Surrogate
biomarkers may be more convenient, ideally predicting long-
term changes in functional disease progression by detecting
small short-term changes.23 Indeed, both visual acuity loss and
atrophic RPE lesions, in which small changes are measurable,
progress over time. Although this relationship may justify using
RPE atrophy as a surrogate, there is a profound disconnect,
particularly in late-onset Stargardt, between the area of RPE
atrophy and vision. This discordance can be explained by
clinically distinct progression subtypes: progression to either a
foveal sparing phenotype in which RPE atrophy encircles the
fovea in a horseshoe- or donut-like fashion (cohort III),7,8,10,22
or a subtype in which no such foveal sparing occurs (cohort
IV). Foveal involvement can determine the eventual vision loss,
either early when the eye has an initially involved fovea, or late
when it exhibits a foveal sparing phenotype.
As discussed above, visual acuity can vary widely, and for
now, unpredictably, depending on the eventual foveal involve-
ment. As the present data show, a large group of 37% with
foveal involvement will do poorly, the rest relatively well. To
determine those patients that would benefit most from
therapy in terms of future clinical trials, analysis of additional
imaging modalities could be helpful. While mottled decreased
areas are difficult to quantify,21 other imaging biomarkers, in
particular, spectral-domain optical coherence tomography,
could indicate what drives the disease process toward foveal
involvement. It has been demonstrated that outer retinal
involvement precedes RPE loss. Specifically, outer nuclear
layer and ellipsoid zone thinning can occur in regions of
normal RPE thickness, suggesting that photoreceptor thinning
may precede RPE degeneration.26 Hence, outer retinal damage
on spectral-domain optical coherence tomography would
precede recognition on FAF. In addition, environmental and
genetic factors could significantly influence the development
of RPE atrophy as identified in atrophic AMD.27,28 Such data
were not included in this study and need to be addressed in
future work.
Further limitations include the retrospective nature of the
study and the resulting heterogeneity of the patients’ data,
which may have been the reason for failing to show
significance between different subtypes of late-onset Stargardt.
For instance, some patients did not report any symptoms, and
were more likely to have no RPE atrophy or only extrafoveal
RPE atrophy not encircling the fovea. These patients would
need a longer follow-up to identify in which direction the
disease will develop. Analogously, heterogeneity within the
imaging data, for example, the fields of view in NIR and FAF
imaging, might have led to the nondetection of more
peripheral atrophic lesions in patients with a 308 field of view,
while such lesions would have been detected in eyes imaged
with a 558 objective.
In recent years, identifying biomarkers in retinal disease has
become a central issue for therapeutic trials that aim to test the
efficacy of a drug. A surrogate outcome measure accepted by
the U.S. Food and Drug Administration is geographic atrophy in
AMD,17 to which areas of RPE atrophy show close similarities.
As this study now has shown that RPE atrophy can also be used
as an outcome measure in late-onset Stargardt, it may even be
valuable in other retinal diseases affecting the RPE. Of special
interest is the precise characterization of late-onset Stargardt
patients; their adult age makes them ethically more appropriate
candidates to participate in clinical trials than patients who are
of minor age. This study provides important knowledge on the
natural history of late-onset Stargardt, quantitatively describing
the course of visual loss and atrophy progression. In addition, it
provides fundamental information necessary to conduct
clinical trials in patients with Stargardt disease.
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